European Journal of Therapeutics
Original Article

Herbal Drug BNO 1016 Versus Fluticasone Propionate Nasal Spray in the Treatment of Chronic Rhinosinusitis without Nasal Polyps: A Preliminary Report

1.

Department of Otorhinolaryngology, Military Medical Academy Faculty of Medicine, University of Defense, Crnotravska 17, Belgrade, Serbia

2.

ENT Hospital “Dr. Žutić”, Belgrade, Serbia

3.

Department of Otorhinolaryngology, University Hospital of Banja Luka Clinical Center, Banja Luka, Bosnia and Herzegovina

4.

Department of Otorhinolaryngology, University Hospital “St. Mother Theresa”, Skopje, Republic of North Macedonia

5.

Institute for Pharmacy, Military Medical Academy Faculty of Medicine, University of Defense, Crnotravska 17, Belgrade, Serbia

Eur J Ther 2020; 26: 192-201
DOI: 10.5152/eurjther.2020.19117
Read: 52 Downloads: 68 Published: 22 September 2020

Objective: Current evidence supports the use of herbal drugs in the reduction of symptoms of acute (ARS) and chronic rhinosinusitis (CRS). Intranasal corticosteroids are the first line treatment option for treating CRS with or without nasal polyps. This study was designed to compare the safety and efficacy of plant medication BNO 1016 and fluticasone propionate nasal spray (FPNS) for treating CRS without nasal polyps (CRSsNP).

Methods: Forty subjects with CRSsNP were randomly divided into two treatment groups that comprised 20 patients each. The patients from Group 1 were treated with herbal drug BNO 1016, tablets of 160 mg, 3×1/d per os, for 28 d. The patients from Group 2 used FPNS 200 μg once daily, 2 puffs in each nostril in the morning for 28 d. We evaluated the nasal total symptom score (TSS), individual scores for each symptom (nasal congestion/obstruction, rhinorrhea/postnasal discharge, facial pain with the sense of pressure, headache, loss of the sense of smell), total endoscopic score (TES), and individual endoscopic signs (edema of the nasal mucosa, nasal secretion, and nasal crusting), before and after the therapy.

Results: TSS was lower on Day 7 (p=0.008), Day 14 (p=0.004), Day 21 (p<0.001), and Day 28 (p=0.002) in patients treated with BNO 1016. Moreover, the TES was lower on Day 21 (p=0.001) and Day 28 (p=0.002) in subjects who were on therapy with BNO 1016. No adverse events were noted in Group 1; however, in patients treated with intranasal glucocorticoids, 2 patients reported mild nasal bleeding, and 1 reported a sense of dryness in the nose.

Conclusion: BNO 1016 could be a good alternative to intranasal corticosteroids in the treatment of CRSsNP without adverse events.

How to cite: Perić A, Gaćeša D, Aleksić A, Kopacheva-Barsova G, Perić AV. Herbal Drug BNO 1016 Versus Fluticasone Propionate Nasal Spray in the Treatment of Chronic Rhinosinusitis without Nasal Polyps: A Preliminary Report. Eur J Ther 2020; 26(3): 192-201.

Files
EISSN 2564-7040